Antiretroviral Medications: Adverse Effects on the Kidney

Advances in Chronic Kidney Disease

Volumn 17, Issue 1, 2010, Pages 72-82

  Jao, Jennifer ^a   Wyatt, Christina M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral; Human immunodeficiency virus; Indinavir; Nephrotoxicity; Tenofovir

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CIDOFOVIR; COTRIMOXAZOLE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VICRIVIROC; ZALCITABINE;

ACUTE KIDNEY FAILURE; DRUG EXPOSURE; DRUG SAFETY; FANCONI ANEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPOPHOSPHATEMIC RICKETS; INTERSTITIAL NEPHRITIS; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE NECROSIS; LONG TERM EXPOSURE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROGENIC DIABETES INSIPIDUS; NEPHROLITHIASIS; NEPHROTOXICITY; OBSTRUCTIVE NEPHROPATHY; PRIORITY JOURNAL; PYURIA; REVIEW; TUBULAR DYSFUNCTION; UROLITHIASIS;

ADENINE; AIDS-ASSOCIATED NEPHROPATHY; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; INDINAVIR; KIDNEY; PHOSPHONIC ACIDS;

EID: 71249098778     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2009.07.009     Document Type: Review

References (122)

1. UNAIDS 2008 Report on the Global AIDS epidemic. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp. Accessed May 14, 2009
2. El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. Strategies for management of Antiretroviral Therapy (SMART) Study Group: CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
3. Gupta S., Eustace J., Winston J.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40 (2005) 1559-1585
4. Jung N., Lehmann C., Rubbert A., et al. Relevance of the organic cation transporters 1and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 36 (2008) 1616-1623
5. Takeda M., Khamdang S., Narikawa S., et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300 (2002) 918-924
6. Leung S., and Bendayan R. Uptake properties of lamivudine (3TC) by a continuous renal epithelial cell line. Can J Physiol Pharmacol 79 (2001) 59-66
7. Cihlar R., Ho E., Lin D., et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20 (2001) 641-648
8. Uwai Y., Ida H., Tsuji Y., et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 24 (2007) 811-815
9. Nelson M., Azwa A., Sokwala A., et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 22 (2008) 1374-1375
10. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med 52 (2006) 296-297
11. Krishnan M., Nair R., Haas M., et al. Acute renal failure in an HIV positive 50 year old man. Am J Kidney Dis 36 (2000) 1075-1078
12. Crowther M.A., Callaghan W., Hodsman A., et al. Dideoxyinosine-associated nephrotoxicity. AIDS 7 (1993) 131-132
13. Izzedine H., Launay-Vacher V., and Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 19 (2005) 844-845
14. D'Ythurbide G., Goujard C., Méchaï F., et al. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: A case report and literature review. Nephrol Dial Transplant 22 (2007) 3656-3659
15. John M., and Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 15 (2002) 23-29
16. Lund K.C., Peterson L., and Wallace K.B. Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother 51 (2007) 2531-2539
17. Boubaker K., Flepp M., Sudre P., et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort Study. Clin Infect Dis 33 (2001) 1931-1937
18. Ray A., Cihlar T., Robinson K., et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50 (2006) 3297-3304
19. Van Rompay K.K., Brignolo L.L., Meyer D.J., et al. Biological effects of short-term or prolonged administration of tenofovir to newborn and infant rhesus macaques. Antimicrob Agents Chemother 48 (2004) 1469-1487
20. Gitman M., Hirschwerk D., Baskin C., et al. Tenofovir-induced kidney injury. Expert Opin Drug Saf 6 (2007) 155-164
21. Gupta S. Tenofovir-associated Fanconi syndrome: review of the FDA Adverse Event Reporting System. AIDS Patient Care STDS 22 (2008) 99-103
22. Kearney B.P., Sayre J.R., Flaherty J.F., et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol 45 (2005) 1360-1367
23. Kearney B.P., Mathias A., Mittan A., et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 43 (2006) 278-283
24. Zimmerman A., Pizzoferrato T., Bedford J., et al. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 42 (2006) 283-290
25. Gallant J., Parish M., Keruly J., et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40 (2005) 1194-1198
26. Winston A., Amin J., Mallon P., et al. Minor changes in calculated creatinine clearance and anion-gap are asoociated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 7 (2006) 105-111
27. Fux C., Simcock M., Wolbers M., et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12 (2007) 1165-1173
28. Young B., Buchacz K., Baker R., et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV outpatient study. J Int Assoc Physicians AIDS Care 6 (2007) 178-187
29. Barbour T.D., Furlong T.J., and Finlayson R.J. Efavirenz-associated podocyte damage. AIDS 21 (2007) 257-258
30. Wirth G.J., Teuscher J., Graf J.D., et al. Efavirenz-induced urolithiasis. Urol Res 34 (2006) 288-289
31. Izzedine H., Valantin M.A., Daudon M., et al. Efavirenz urolithiasis. AIDS 21 (2007) 1992
32. Angel-Moreno-Maroto A., Suarez-Castellano L., Hernandez-Cabrera M., et al. Severe efavirenz-induced hypersensitivity syndrome (not DRESS) with acute renal failure. J Infect 52 (2006) e39-e40
33. Curry E., Thomas M., and Yehia M. Renal impairment and hypersensitivity reaction due to efavirenz. Nephrology 13 (2008) 541
34. Knudtson E., Para M., Boswell H., et al. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol 101 (2003) 1094-1097
35. Madruga J., Cahn P., Grinsztejn B., et al. Efficacy and safety of TMC125 (etravirine)in treatment-experienced HIV-1-infected patients in DUET-1: 24 week results from a randomized, double-blind, placebo-controlled trial. Lancet 370 (2007) 29-38
36. Lazzarin A., Campbell T., Clotet B., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24 week results from a randomized, double-blind, placebo-controlled trial. Lancet 370 (2007) 39-47
37. Duong M., Sgro C., Grappin M., et al. Renal failure after treatment with ritonavir. Lancet 348 (1996) 693
38. Stricker R.B., Man K.M., Bouvier D.B., et al. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 349 (1997) 1745-1746
39. Engeler D.S., John H., Rentsch K.M., et al. Nelfinavir urinary stones. J Urol 167 (2002) 1384-1385
40. Feicke A., Rentsch K., Oertle D., et al. Same patient, new stone composition: Amprenavir urinary stone. Antivir Ther 13 (2008) 733-734
41. Green S.T., McKendrick M.W., Schmid M.L., et al. Renal calculi developing de novo in a patients taking saquinavir. Int J STD AIDS 9 (1998) 555-958
42. Doco-Lecompte T., Garrec A., Thomas L., et al. Lopinavir/ritonavir (Kaletra) and lithiasis: seven cases. AIDS 18 (2004) 705-706
43. Gagnon R., Tecimer S., Watters A., et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 36 (2000) 507-515
44. Kopp J., Miller K., Mican J., et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 127 (1997) 119-125
45. Balani S., Arison B., Mathai L., et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 23 (1995) 266-270
46. Dieleman J., Sturkenboom M., Jambroes M., et al. Risk factors for the urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: The ATHENA cohort. Arch Intern Med 162 (2002) 1493-1501
47. Sarcletti M., Petter A., Romani N., et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 54 (2000) 261-270
48. Van Rossum A., Dieleman J., Fraaij P., et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatrics 110 (2002) 1-7
49. Kopp J., Falloon J., Filie A., et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 99 (2002) 1122-1128
50. Dieleman J., van der Feltz M., Bangma C.H., et al. Papillary necrosis associated with the HIV protease inhibitor indinavir. Infection 29 (2001) 232-233
51. Iba-Ba J., Yombi J., Danse E., et al. Nécrose papillaire bilatérale lors d'un traitement par indinavir. Presse Med 37 (2008) 967-969
52. Hanabusa H., Tagami H., and Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 340 (1999) 392-393
53. Reyataz. Product information (June 2006), Bristol-Myers Squibb Company, Princeton, NJ
54. Chang H. Atazanavir urolithiasis. N Engl J Med 355 (2006) 2158-2159
55. Pacanowski J., Poirier J.M., Petit I., et al. Atazanavir urinary stones in an HIV-infected patient. AIDS 20 (2006) 2131
56. Chan-Tack K., Truffa M., Struble K., et al. Atazanavir-associated nephrolithiasis: Cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 21 (2007) 1215-1218
57. Couzigou C., Daudon M., Meynard J., et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 45 (2007) e105-e108
58. Brewster U., and Perazella M. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 44 (2004) e81-e84
59. Wild C., Greenwell T., and Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 9 (1993) 1051-1053
60. Tebas P., Bellos N., Lucasti C., et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure. J Acquir Immune Defic Syndr 47 (2008) 342-345
61. Gulick R., Lalezari J., Goodrich J., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359 (2008) 1429-1441
62. Gulick R., Su Z., Flexner C., et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1 infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 196 (2007) 304-312
63. Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs 15 (2006) 1507-1522
64. Steigbigel R., Cooper D., Kumar P., et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359 (2008) 339-354
65. DeJesus E., Berger D., Markowitz M., et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 43 (2006) 1-5
66. Zolopa AR, Mullen M, Berger D, et al: The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients [Oral Presentation 143LB]. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007, Los Angeles, CA
67. Zolopa AR, Lampiris H, Blick G, et al. The HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral Activity in Treatment-Experienced Patients with Active Optimized Background Therapy (OBT) [Oral Presentation]. Paper presented at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2007, Chicago, IL
68. Grinspoon S., Grunfeld C., Kotler D., et al. State of the Science Conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS Executive Summary. Circulation 118 (2008) 198-210
69. Friis-Møller N., Sabin C.A., Weber R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
70. Friis-Møller N., Reiss P., Sabin C.A., et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007) 1723-1735
71. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371 (2008) 1417-1426
72. Triant V.A., Lee H., Hadigan C., et al. Increased acute myocardial infarction rates and cardiovascular risk factors amont patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92 (2007) 2506-2512
73. Bozzette S., Ake C., Tam H., et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47 (2008) 338-341
74. Grunfeld C., Pang M., Doerrler W., et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74 (1992) 1045-1052
75. Riddler S.A., Smit E., Cole S.R., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 289 (2003) 2978-2982
76. Kotler D.P. HIV and antiretroviral therapy: Lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 49 (2008) S79-S85
77. Justman J., Benning L., Danoff A., et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 32 (2003) 298-302
78. Brown T., Li X., Cole S., et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 19 (2005) 1375-1383
79. Moor M.A., Flint O., Maa J., et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20 (2006) 1813-1821
80. Molina J.M., Andrade-Villanueva J., Echevarria J., et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372 (2008) 646-655
81. Madruga J.V., Berger D., McMurchie M., et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370 (2007) 49-58
82. Gallant J., Staszewski S., Pozniak A., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. JAMA 29 (2004) 191-201
83. Tebas P., Powderly W.G., Claxton S., et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14 (2000) F63-F67
84. Nolan K., Upton R., McKinnon E., et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15 (2001) 1275-1280
85. Mondy K., Yarasheski K., Powderly W., et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36 (2003) 482-490
86. Rivas P., Górgolas M., García-Delgado R., et al. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 9 (2007) 89-95
87. Mora S., Zamproni I., Beccio S., et al. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 89 (2004) 24-28
88. Giacomet V., Mora S., Martelli L., et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr 40 (2005) 448-450
89. Gafni R., Hazra R., Reynolds J., et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118 (2006) e711-e718
90. Van Rompay K., Durand-Gasselin L., Brignolo L., et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52 (2008) 3144-3160
91. Sheehan M.T., and Wen S.F. Hyperkalemic renal tubular acidosis induced by trimethoprim/sulfamethoxazole in an AIDS patient. Clin Nephrol 50 (1998) 188-193
92. Porras M.C., Lecumberri J.N., and Castrillon J. Trimethoprim/sulfamethoxazole and metabolic acidosis in HIV-infected patients. Ann Pharmacother 32 (1998) 185-189
93. Velazquez H., Perazella M., Wright F.S., et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 119 (1993) 296-301
94. Perazella M.A., and Mahnensmith R.L. Trimethoprim-sulfamethoxazole: Hyperkalemia is an important complication regardless of dose. Clin Nephrol 46 (1996) 187-192
95. Alapan R., Perazella M.A., and Buller G.K. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 124 (1996) 316-320
96. Reiser I., Chou S., Brown M., et al. Reversal of trimethoprim-induced antikaliuresis. Kidney Int 50 (1996) 2063-2069
97. Perazella M.A. Trimethoprim-induced hyperkalemia: Clinical data, mechanism, prevention, and management. Drug Saf 22 (2000) 227-236
98. De Vriese A., Robbrecht D., Vanholder R., et al. Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features. Am J Kidney Dis 31 (1998) 108-115
99. Covic A., Goldsmith D., Segall L., et al. Rifampicin-induced acute renal failure: A series of 60 patients. Nephrol Dial Transplant 13 (1998) 924-929
100. De Jager P., and Van Altena R. Hearing loss and nephrotoxicity in longterm aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 6 (2002) 622-627
101. Wingard J.R., Kubilis P., Lee L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29 (1999) 1402-1407
102. Moreau P., Milpied N., Fayette N., et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 30 (1992) 535-541
103. Luber A.D., Maa L., Lam M., et al. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 43 (1999) 267-271
104. Bates D.W., Su L., Yu D.T., et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 60 (2001) 1452-1459
105. Becker B.N., Fall P., Hall C., et al. Rapidly progressive acute renal failure due to acyclovir: A case report and review of the literature. Am J Kidney Dis 22 (1993) 611-615
106. De Miranda P., and Blum M.R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 12 suppl B (1983) 29-37
107. Sawyer M.H., Webb D., Balow J., et al. Acyclovir-induced renal failure. Am J Med 84 (1988) 1067-1071
108. Schmidt G.M., Horak D.A., Niland J.C., et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 324 (1991) 1005-1011
109. Czock D., Scholle C., Rasche F.M., et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 72 (2002) 142-150
110. Ljungman P., Deliliers G., Platzbecker U., et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 97 (2001) 388-392
111. Lalezari J.P., Holland G., Kramer F., et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr 17 (1998) 339-344
112. Polis M., Spooner K., Baird B., et al. Anticytomegaloviral activity and safety of cidofovir in patients in human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 39 (1995) 882-886
113. Cundy K.C., Petty B., Flaherty J., et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 39 (1995) 1247-1252
114. Kahn J., Lagakos S., Wulfsohn M., et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA 282 (1999) 2305-2312
115. Fisher E., Chaloner K., Cohn D., et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: A randomized, placebo-controlled trial. AIDS 15 (2001) 1695-1700
116. Izzedine H., Hulot J.S., Launay-Vacher V., et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int 66 (2004) 1153-1158
117. Ha N.B., Ha N.B., Garcia R.T., et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology (2009) Epub ahead of print
118. Deray G., Martinez F., Katlama C., et al. Foscarnet nephrotoxicity: Mechanism, incidence and prevention. Am J Nephrol 9 (1989) 316-321
119. Jacobson M.A. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr 5 suppl 1 (1992) S11-S17
120. Maurice-Estepa L., Daudon M., Katlama C., et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 32 (1998) 392-400
121. Navarro J., Quereda C., Quereda C., et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 27 (1996) 431-434
122. Deray G., Katlama C., and Dohin E. Prevention of foscarnet nephrotoxicity. Ann Intern Med 113 (1990) 332